Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc develops and markets pharmaceuticals for the treatment of central nervous system diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Supernus Pharmaceuticals stock, expecting it to rise toward $45.25.
Financial Health
Supernus Pharmaceuticals is performing well with strong profits, cash flow, and revenue generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SUPN
Domestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketBeyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Focused CNS Portfolio
Supernus concentrates on central nervous system therapies such as ADHD and epilepsy, which can offer targeted market opportunities though sales hinge on a few key products.
Growth Drivers To Watch
Pipeline progress, label expansions and new launches can drive revenue, but regulatory outcomes and competition may cause performance to vary.
Commercial & Regulatory Risks
Pricing, reimbursement and patent timelines shape profitability; investors should weigh these structural risks alongside potential upside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
